ArticleMolecular biotechnology2026
DAPK3-Ablation Regulates the AMPK/mTOR-GPX4 Signaling Pathway to Affect Biological Functions of Staphylococcus aureus-Treated Bone Marrow Mesenchymal Stem Cells and Potentially Ameliorate Osteomyelitis.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Osteomyelitis: Epidemiology, Classification, Pathophysiology, Clinical Features, Diagnosis, and Management.MedComm · 2026Review
- Regulated Cell Death Pathways in Chondrocytes During Septic Arthritis: Current Evidence and Future Perspectives.Journal of inflammation research · 2026Review
- HIF-1α at the intersection of hypoxia, ferroptosis-associated stress, and cell death crosstalk in osteomyelitis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Staphylococcus aureus (SA)-caused osteomyelitis (OM) is inflammation-related refractory disease that seriously degrades the life quality of human beings. Unfortunately, up until now, the molecular mechanisms of OM progression have not been fully delineated, which hampered the development of treatment strategies for this disease. The present study aimed to resolve this issue and a novel DAPK3/AMPK/mTOR-GPX4 signal pathway was significantly linked to the development of OM. Specifically, the rat bone marrow mesenchymal stem cells (rBMSCs) were treated with SA to establish the OM models. SA treatment triggered cell autophagy and ferroptosis and suppressed osteogenic differentiation of rBMSCs. Mechanistically, as it was revealed by our RNA sequencing analysis and cellular experiments, SA significantly increased the expression levels of DAPK3 in a dose-dependent manner, and silencing DAPK3 reversed SA-induced detrimental effects in rBMSCs. Of note, our subsequent experiments confirmed that DAPK3-ablation reduced the phosphorylation of AMPK and ULK1, while increasing the phosphorylation of mTOR and the expression of GPX4. The improvement effects of DAPK3 deficiency on cell autophagy, ferroptosis, and osteogenic differentiation in SA-treated rBMSCs were abrogated by co-treating cells with AMPK activator. In summary, this research verified that silencing of DAPK3 regulated the AMPK/mTOR-GPX4 signal pathway to modulate cell autophagy, ferroptosis and osteogenic differentiation, ameliorating OM progression.
Indexed as
Identifiers
40601185What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.